

June 4, 2020



# Atara Biotherapeutics to Participate at Two Upcoming Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- [Atara Biotherapeutics, Inc.](#) (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Pascal Touchon, the Company's President and Chief Executive Officer, will participate at two upcoming virtual conferences in June.

## **Goldman Sachs 41<sup>st</sup> Annual Global Healthcare Conference**

Video Fireside Chat: Thursday, June 11, 2020 at 3:50 p.m. EDT

A live video webcast of the Goldman Sachs presentation will be available by visiting the [Investor Events and Presentations](#) section of [atarabio.com](#). An archived replay will be available on the Company's website for approximately 14 days following the live webcast.

## **BIO Digital**

Company Presentation: available on-demand via the [BIO website](#), June 8-12, 2020

## **About Atara Biotherapeutics, Inc.**

[Atara Biotherapeutics, Inc.](#) ([@Atarabio](#)) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other severe diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel<sup>®</sup> (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. For additional information about the company, please visit [atarabio.com](#) and follow us on [Twitter](#) and [LinkedIn](#).

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20200604005149/en/>

**Media**

Kerry Beth Daly  
Head, Corporate Communications  
Atara Biotherapeutics  
516-982-9328  
[kdaly@atarabio.com](mailto:kdaly@atarabio.com)

***Investors***

Eric Hyllengren  
Vice President, Investor Relations & Finance  
Atara Biotherapeutics  
805-395-9669  
[ehyllengren@atarabio.com](mailto:ehyllengren@atarabio.com)

Source: Atara Biotherapeutics, Inc.